Participants
Jan Talts
COO, Amniotics AB
Address: Amniotics AB, Scheelevägen 2, Building 406, SE-223 81 Lund, Sweden
Phone: +46 72-327 8530
E-mail: jt@amniotics.com
Homepage: www.amniotics.com
Amniotics AB is a stem cell company, focused on developing innovative and regenerative medicine
Jan Talts has extensive R&D and management experience from academia, the biotech industry, and the health care sector. He earned his PhD in Animal Physiology at Uppsala University working with extracellular matrix molecules in development and disease and has since then held positions as Associate Professor in Cell and Molecular Biology at Lund University, Associate Professor and Section Leader for Anatomy and Cell Biology at the Royal Veterinary and Agricultural University, Copenhagen, Chief Medical Staff, Clinical Pathology, Lund University Hospital, and Senior Scientist at Xintela AB, a biomedical company working in the fields of stem cell therapy and targeted cancer therapy. Since 2017 he has been developing and producing Advanced Therapy Medicinal Products (ATMP), first as Senior Scientist, then Head of Quality and now Chief Operating Officer and QP at Amniotics AB.
Axel Schambach
Dr. med. and PhD
Axel Schambach, Dr. med. and PhD, is Director of the Institute of Experimental Hematology and Professor for Gene Modification of Somatic Cells (W3) at Hannover Medical School (MHH).
He studied medicine in Hamburg, San Diego, San Francisco, Dallas and Zürich received his PhD in Molecular Medicine. He is a group leader in the Excellence cluster REBIRTH since 2007 and continues to work in the REBIRTH Center for Translational Regenerative Medicine. From 2012 on, he serves as adjunct faculty at Boston Children’s Hospital at Harvard Medical School. His main research interest is to understand the molecular pathophysiology of inborn and acquired diseases to develop tailor-made gene therapy and molecular medicine strategies, incl. immunotherapies. Here he focuses on novel gene delivery tools, including state-of-the-art integrating vectors and designer nucleases as well as new stem cell-based strategies and disease modeling.
Søren Skov
Professor
Søren Skov is professor in Immunology at University of Copenhagen, Denmark at the Section for Preclinical Disease Biology. He obtained his PhD from University of Copenhagen on regulation of T cells through MHC Class I molecules, and did his post doc in Seattle at Xcyte Therapies Inc. identifying novel forms of T cell regulation.
Søren Skov’s laboratory currently investigates how different leukocytes are regulated during cancer and inflammation, with a particular interest in regulation of innate lymphocytes like NK cells and gamma/delta T-cells using state of the art in vitro and in vivo technologies. The laboratory have a wide spread collaborative network of academic and industrial partners.
Niels-Bjarne Woods
Associate Professor, Lund University, Sweden
Address: Lund‘s Stem Cell Center, BMC A12, 22184, Lund, Sweden
Phone: +46 46 222 3762
E-mail: niels-bjarne.woods@med.lu.se
Homepage: https://www.stemcellcenter.lu.se/research-groups/woods
Niels-Bjarne Woods has been a driver of innovative research in stem cell biology and hematopoietic development for over 2 decades. He is Associate Professor at Lund University’s Stem Cell Center where he leads the Hematopoietic Stem Cell Development Laboratory. He earned his PhD for work in genetic engineering of stem cells at Lund University, Sweden, and completed Post Doctoral training at the Salk Institute for Biological Studies, La Jolla, California. Shortly after being recruited to the Lund Stem Cell Center in 2009, he began his pioneering work with induced pluripotent stem cells to mimic development of human blood, his primary focus today. He has identified numerous novel regulators of hematopoietic cell development and has received numerous awards for driving this research program. Most recently, he has identified the role of metabolic regulation in directing NK cell development from pluripotent stem cells. In a parallel interest, he has also identified key features of Amniotic fluid derived cells, including tissue specific amniotic fluid cells. He has generated numerous patents from his research activities which are foundational to many of the research and clinical activities at Amniotics AB, to which he is also cofounder.